Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects.